- Home
- Â /Â FORMA Therapeutics
FORMA Therapeutics
Stock Price
$20
2022-10-21
Market Capitalization
$998.7 M
2022-10-21
FORMA Therapeutics Summary
Company Summary
- Overview
- FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines. It has two core product candidates for development: FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Watertown, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
David N. Cook, Senior Vice President, Chief Scientific Officer
Jeannette Potts, Senior Vice President, General Counsel & Corporate Secretary
Todd Shegog, Senior Vice President, Chief Financial Officer
FORMA Therapeutics Financials
Summary Financials
- Net income (Q2, 2022)
- ($52.6M)
- EBIT (Q2, 2022)
- ($53.0M)